Log In
Print
BCIQ
Print
Print this Print this
 

ImMucin (VXL100)

  Manage Alerts
Collapse Summary General Information
Company Vaxil BioTherapeutics Ltd.
Description21mer synthetic vaccine composed of the entire signal peptide domain of the mucin 1 (MUC1; CD227) protein
Molecular Target Mucin 1 (MUC1) (CD227)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I/II
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat MUC1-positive tumors; Treat multiple myeloma (MM)
Regulatory Designation

U.S. - Orphan Drug (Treat multiple myeloma (MM));
EU - Orphan Drug (Treat multiple myeloma (MM))

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today